Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
LIVONIA, Mich., March 13, 2018 -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia, non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), today announced that it will host a conference call and live audio webcast on Thursday, March 15, 2018 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2017 and to provide a business update.
| Thursday, March 15 at 4:30pm Eastern Time | |
| Domestic: | (844) 494-0188 |
| International: | +1 (425) 278-9114 |
| Conference ID | 2090268 |
| Webcast: | https://edge.media-server.com/m6/p/bxoocvxs |
A webcast replay will be available on the News & Events section of the Gemphire website for all interested parties following the call and will be archived and available for 90 days.
About Gemphire
Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene as add-on to the standard of care, especially statins, that will benefit patients, physicians, and payors. Gemphire’s Phase 2 clinical program is evaluating the efficacy and safety of gemcabene in hypercholesterolemia, including FH and ASCVD, SHTG and NASH/NAFLD. Two trials supporting hypercholesterolemia have been completed under NCT02722408 and NCT02634151. Gemphire has completed recruitment for a clinical trial for SHTG under NCT02944383, and has initiated separate trials for adult NASH and pediatric NAFLD. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
